2015 Volume 16 Issue 3 Pages 141-146
Bone-Modifying Agents (BMA), such as bisphosphonates and denosumab are useful medicine that suppresses Skeletal-Related Event (SRE), and improves patient's prognosis and quality of life. However, the possible adverse event of osteonecrosis of the jaw (ONJ) is a severe problem. Risk factors of ONJ are dental infection and extraction. Those dental problems should be treated before administering BMA. And, when ONJ develops, dentist's participation is necessary. Therefore, the cooperation of doctors using BMA and a dentist is important. In order to promote the medical treatment cooperation in administering BMA safely, we organized “Liaison meeting for BMA”. Members consisted of physicians, dentists, and pharmacists. Our purposes are follows：
1. Mutual understanding of multi occupational category concerning ONJ by BMA
2. Construction of system for BMA treatment
13 meetings were held by June, 2014, including study meetings and lecture meetings where the system for the BMA treatment was prepared. As a result, 12 patients used the system by present, and all patients outcome are good. We will support the safe use of BMA by introducing the system to various medical institutions.
